Celosia Therapeutics, an Australian biotech company focused on gene therapies for neurodegenerative diseases, has introduced CTx1000 designed to target the pathological TDP-43 protein, a key factor in ALS. On March 23, 2026, the company disclosed the initiation of dosing for the first participant in their trial. This promising development marks a significant step forward in combating ALS, a debilitating condition that affects millions worldwide. The therapy's potential impact is substantial, with the hope of revolutionizing treatment options for patients with ALS. The research and development efforts by Celosia Therapeutics underscore their commitment to advancing medical science and improving patient outcomes in the field of neurodegenerative disorders.